Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-small Cell Lung Cancer Metastatic × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 16 Prostatic Neoplasms 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Leukemia 2 Healthy Participants 2 Endometrial Neoplasms 2 Disease Progression 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Non-small Cell Lung Cancer Metastatic 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1

Interventions

pembrolizumab 3 Bevacizumab 3 tusamitamab ravtansine 2 Ramucirumab 2 Pemetrexed 2 Gemcitabine 2 Erlotinib Hydrochloride 2 Docetaxel 2 Carboplatin 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2 vistusertib 1 vandetanib 1 telomerase reverse transcriptase p572Y, human 1 spartalizumab 1 sotorasib 1 olaparib 1 necitumumab 1 icotinib 1 durvalumab 1 dacomitinib 1 capivasertib 1 aumolertinib 1 Vinorelbine 1 Radiosurgery 1 Platinum 1 Paclitaxel 1 MLN 8237 1 LY3023414 1 Injections 1 GC Temporary Stopping 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02117167 2024-01-10

SAFIR02_Lung

UNICANCER

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡